ARTICLE | Clinical News
HE2000: Began Phase II study
October 8, 2001 7:00 AM UTC
Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Product: HE2000 Business: Infectious diseases Therapeutic category: Immune modulation Target: Host cell factors including glucose-6-phosphat...